➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Harvard Business School
Dow
Express Scripts
Medtronic

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,512,200

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,512,200
Title:Personalized production of biologics and method for reprogramming somatic cells
Abstract: The invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.
Inventor(s): Deisher; Theresa A. (Seattle, WA)
Assignee: AVM Biotechnology, LLC (Seattle, WA)
Application Number:13/342,704
Patent Claims:see list of patent claims

Details for Patent 9,512,200

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CEREZYME imiglucerase INJECTABLE;INJECTION 020367 001 1995-04-07   Start Trial AVM Biotechnology, LLC (Seattle, WA) 2031-01-03 RX search
Genzyme CEREZYME imiglucerase INJECTABLE;INJECTION 020367 002 1995-04-07   Start Trial AVM Biotechnology, LLC (Seattle, WA) 2031-01-03 RX search
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 001 2003-04-24   Start Trial AVM Biotechnology, LLC (Seattle, WA) 2031-01-03 RX Orphan search
Genzyme FABRAZYME agalsidase beta VIAL; INTRAVENOUS 103979 002 2003-04-24   Start Trial AVM Biotechnology, LLC (Seattle, WA) 2031-01-03 RX Orphan search
Biomarin ALDURAZYME laronidase VIAL 125058 001 2003-04-30   Start Trial AVM Biotechnology, LLC (Seattle, WA) 2031-01-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Boehringer Ingelheim
Dow
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.